Entries by

Virtual Incision Announces MIRA’s Clinical Trial Results Will Be Presented at the 2023 ASCRS Scientific Meeting

Attendees will be the first to see outcomes from the complete patient series within MIRA’s Investigational Device Exemption clinical study LINCOLN, Neb. – May 31, 2023 – Virtual Incision Corporation, the developer of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced that the data from its Investigational Device Exemption (IDE) clinical trial will […]

May 31, 2023 by

The MIRA Surgical System Proceeds to FDA Substantive Review for Market Authorization Under the De Novo Classification Pathway

Virtual Incision Has Achieved a Significant Milestone in Its De Novo Request and is Closer to Potential Commercial Readiness  Lincoln, Neb. – May 18, 2023 – Virtual Incision Corporation today announced its De Novo request was submitted and is under substantive review by the U.S. Food and Drug Administration (FDA). The submission seeks authorization to […]

May 18, 2023 by

The Innovation Continues for Robotic-Assisted Surgery – Virtual Incision Completes FDA Investigational Device Exemption Clinical Study of MIRA

Lincoln, Neb. – February 22, 2023 – Virtual Incision Corporation, a medical device company spearheading the development of the world’s first miniaturized robotic-assisted surgery (RAS) system, today announced the completion of its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical study. The study was designed to evaluate the company’s MIRA Surgical System for use in bowel resection procedures. This is an important achievement towards bringing new technologies to hospitals and their surgical robotics programs regardless of the site of care.

February 22, 2023 by

Contact

Sign up today to be the first to get Virtual Incision news and updates

SIGN UP
2022 © Copyright - Virtual Incision®